Daptomycin exposure precedes infection and/or colonization with daptomycin non-susceptible enterococcus

Table 2 Characteristics of patients with respect to prior daptomycin exposure

	Prior Daptomycin Exposure	No Daptomycin Exposure	P value*
Number of Isolates	15 (60%)	10 (40%)	--
Age	52.5	51.8	--
Sex – no (%)
-Female	8/15 (53%)	6/10 (60%)	0.742
Isolate
-E. faecium	14 (93%)	4 (67%)	0.115
-E. faecalis	0 (0%)	2 (33%)	0.019
-Species Not Identified	1 (7%)	0 (0%)	--
-Isolate Not Available^a	0	4	--
Source
-Blood^b	7 (47%)	2 (20%)	0.174
-Urine^b	5 (33%)	7 (70%)	0.072
-Peritoneal Fluid	2 (13%)	1 (10%)	0.802
-Wound	2 (13%)	0 (0%)	0.229
-Colonization^c	4 (27%)	4 (40%)	0.484
Past Medical History
-Diabetes	6 (40%)	6 (60%)	0.327
-ESRD/Dialysis	2 (13%)	1 (10%)	0.802
-Cancer/Chemotherapy^d	8 (53%)	4 (40%)	0.513
-History of Transplant	2 (13%)	0 (0%)	0.229
-CVD^e	3 (20%)	4 (40%)	0.275
-Lung Disease^f	2 (13%)	2 (20%)	0.656
GI or Intra-abdominal Process^g	12 (80%)	7 (70%)	0.566
Immunosuppression^h	14 (93%)	7 (70%)	0.119
Deathⁱ	8 (53%)	2 (20%)	0.096

Note:
* - All P values were calculated with the use of the chi-square test.
a – Four isolates were not available for species identification.
b – One patient with DNSE and prior daptomycin exposure had DNSE isolated from both blood and urine.
c – All colonizing isolates were obtained from urine of patients without symptoms and/or negative urinalysis.
d – includes all patients with acute lymphoblastic leukemia, acute myelogenous leukemia, myelodysplastic syndrome, bone marrow transplant, stem cell transplant, solid organ tumor, and those undergoing chemotherapy.
e – includes all patients with coronary artery disease, congestive heart failure, cerebro-vascular accident, peripheral vascular disease, and valvular heart disease.
f – includes all patients with chronic obstructive pulmonary disease and pulmonary hypertension.
g – includes all patients with Clostridium difficile infection, graft-versus-host-disease of the gut, neutropenic enterocolitis/perforation, traumatic bowel perforation, bowel ischemia, bacterial peritonitis, ascending cholangitis, gastroparesis, pyelonephritis and/or kidney abscess, or other gastrointestinal surgery with complications.
h – includes all patients with any cancer or undergoing chemotherapy, diabetes mellitus, ESRD/HD, organ transplant.
i – Hospital and/or thirty-day mortality from any cause.

ISSN: 2047-2994